Alisertib (MLN8237)

Catalog No.S1133

Alisertib (MLN8237) Chemical Structure

Molecular Weight(MW): 518.92

Alisertib (MLN8237) is a selective Aurora A inhibitor with IC50 of 1.2 nM in a cell-free assay. It has >200-fold higher selectivity for Aurora A than Aurora B. Phase 3.

Size Price Stock Quantity  
In DMSO USD 168 In stock
USD 120 In stock
USD 210 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 48 Publications

12 Customer Reviews

  • Inhibition of Aurka kinase activity by MLN8237 impairs expression of pluripotency genes in CCE cells as measured by qRT-PCR. All values shown are mean ?SEM for n=3. The level of phosphorylated H3(S10) (p-H3(S10)), an Aurka phosphorylation target site, is decreased in MLN8237-treated samples.

    Cell Stem Cell 2012 11, 179-94. Alisertib (MLN8237) purchased from Selleck.

    Recruitment of clathrin to the mitotic spindle is controlled by phosphorylation of TACC3 by Aurora-A kinase. Representative micrographs of HEK293 cells incubated with 0.3 μM MLN8237 for 40 min. Cells were fixed and stained as indicated.

    EMBO J 2012 30, 906-19. Alisertib (MLN8237) purchased from Selleck.

  • Aurora A inhibition rescues the PPP6C depletion phenotype. (A) HeLa cells transfected for 48 h with control and PPP6C si08 duplexes were treated with 10 or 20 nM MLN8237 or a solvent control for 15 min before lysis in phosphatase inhibitor containing buffer or fixation. Total lysates were analyzed by Western blotting. The red and black lines indicate the hosphorylated and nonphosphorylated forms of Aurora A. Fixed cells were stained using DAPI to detect DNA and antibodies to α-tubulin and Aurora A pT288. The intensity of pT288 staining was integrated using ImageJ over the spindle region defined by TPX2 staining and is plotted in the bar graph ( n = 4). Arrowheads indicate micronuclei. Bar, 5 µm. (B) HeLa cells transfected for 48 h with control and PPP6C si08 duplexes were treated with 10 nM MLN8237 or a solvent control for 24 h before fixation and staining with DAPI to detect DNA.

    J Cell Biol 2010 191, 1315-32. Alisertib (MLN8237) purchased from Selleck.

    NUSAP mitotic phosphorylation at Ser 240 correlates with Aurora A activity. Protein samples of FLAG-NUSAP immunoprecipitated from I, M and MtMLN or with MtZM were analysed using LC-MS/MS, focusing on the predicted phosphorylated residue Ser 240. The histograms (A, B) show the calculated ratios based on peptides carrying the phosphorylated Ser 240 compared with all matched peptides containing this residue.

     

     

    EMBO reports 2010 11, 977-984. Alisertib (MLN8237) purchased from Selleck.

  • D) Pharmacological inhibition of AURKA using alisertib led to downregulation of p-EIF4E (S209) and c-MYC proteins in FLO-1 and SK-GT-4 resistant cells, with or without RAD001 treatment.

    Clin Cancer Res, 2017.. Alisertib (MLN8237) purchased from Selleck.

    Tissue levels of 53BP1, a-tubulin, IkB-a and IL-6 in an Hs294T xenograft treated with MLN8237 or vehicle control were visualized by immunofluorescence co-staining with DAPI. Representative micrographs are shown from triplicate experiments.

    EMBO Mol Med 2013 5(1), 149-66. Alisertib (MLN8237) purchased from Selleck.

  • Alisertib inhibits AURKA and AURKB in a concentration-dependent manner. (a) Alisertib induces G 2 /M delay or genome reduplication. HeLa cells were exposed to buffer or the indicated concentrations of Alisertib. After 24 h, the cells were harvested and analyzed with flow cytometry. The positions of 2N, 4N and 8N DNA contents are indicated. (b) Alisertib delays mitotic exit or induces slippage. HeLa cells stably expressing histone H2B-GFP were exposed to buffer or the indicated concentrations of Alisertib. Individual cells were then tracked for 24 h with time-lapse microscopy. Each horizontal bar represents one cell (n ¼ 50). Key: light gray ¼ interphase; black ¼ mitosis (from DNA condensation to anaphase or mitotic slippage); dark gray ¼ interphase after mitotic slippage; truncated bars ¼ cell death. (c) Different concentrations of Alisertib are involved in delaying mitotic exit and inducing slippage. Live-cell imaging of cells treated with Alisertib was described in panel (b). The duration of mitosis (mean±90% confidence interval) and the percentage of cells that underwent mitotic slippage during the imaging period was quantified. (d) Alisertib promotes apoptosis in a concentration-dependent manner. HeLa cells were incubated with the indicated concentrations of Alisertib for 48 h. The cells were then harvested and analyzed with flow cytometry. (e) Concentration-dependent cytotoxicity of Alisertib. HeLa cells were cultured in the presence of the indicated concentrations of Alisertib for 48 h. The number of live and dead cells was analyzed with trypan blue exclusion assay. (f) Concentration-dependent suppression of long-term survival by Alisertib. HeLa cells were seeded on 60-mm culture plates and grown in the presence of 250 n M or 1 m M of Alisertib. After 24 h, the cells were washed gently and propagated in normal medium for another 10–12 days. Colonies were fixed and stained with crystal violet solution (examples of the plates are shown). Average±s.d. from three independent experiments. (g) Both AURKA and AURKB are inhibited by Alisertib.Mitotic HeLa cells were obtained by exposure to nocodazole for 16 h followed by mechanical shake off. The cells were incubated with the indicated concentrations of Alisertib for 2 h. Lysates were then prepared and activated phospho-AURKAThr288 and AURKBThr232were detected with immunoblotting. The asterisk indicates the position of an AURKB-like protein (the same throughout this study). Uniform loading was confirmed by immunoblotting for actin. In this assay, nocodazole and MG132 (a proteasome inhibitor) were added to prevent the cells from exiting mitosis. Accordingly, the total AURKA and AURKB levels remained constant throughout the experiment. (h) Alisertib prevents activation of AURKA and AURKB. HeLa cells were incubated with the indicated concentrations of Alisertib for 8 h. Nocodazole was then added for another 6 h to trap cells that entered mitosis. Lysates were prepared and analyzed with immunoblotting. Actin analysis was included to assess loading and transfer.

    Oncogene 2014 33, 3550-60. Alisertib (MLN8237) purchased from Selleck.

    Inhibition of Aurora A (12.5 nM) by MLN8054 or MLN8237 was assessed in duplicate radiometric assays containing 100 μM [γ-32P] ATP and quantified by p81 phosphocellulose assay and scintillation counting. Kinase activity is reported as a percentage of control calculated from duplicate incubations containing 2.5% (v/v) DMSO. IC50 values represent the mean ±SEM calculated from two independent experiments.

     

     

    ACS Chem Biol 2010 5, 563-576. Alisertib (MLN8237) purchased from Selleck.

  • The effects of T217D and T217N Aurora A mutations were directly compared to WT Aurora A-expressing cells. Each well was treated with either DMSO or 500 nM MLN8054 (E), or 30 nM MLN8237 (F) on day one of the experiment and cells were cultured for 8 days, at which point they were fixed. For all colony assays, an area encompassing >90 % of the colonies per dish is shown. Similar results were seen in two independent duplicate experiments.

    ACS Chem Biol 2010 5, 563-576. Alisertib (MLN8237) purchased from Selleck.

    C, Fry depletion decreases the level of Thr-210 phosphorylation of Plk1 on spindle poles. HeLa cells transfected with siRNAs were cultured in growth medium for 12 h and in thymidine-containing medium for 36 h. They were then released from thymidine arrest for 12 h before being fixed and stained with anti-Plk1 pT210 ( green) and anti-pericentrin (red) antibodies. DNA was stained with TO-PRO-3 ( blue ). For Aurora A inhibition, after release from thymidine block for 10 h, HeLa cells transfected with control siRNA were incubated for2h in medium containing MLN8237 (100 nM) and MG132 (10 μM). Magnified images of the white boxes are also shown. Scale bar ,5 μm.

    J Biol Chem 2012 287, 27670-81. Alisertib (MLN8237) purchased from Selleck.

  • B, drug-treated cells were also stained with DAPI to visualize nuclear DNA and analyzed with a microscope equipped with a fluorescence digital CCD camera. Representative results are shown. Bar, 40 μm.

    J Biol Chem, 2017, 292(5):1910-1924. Alisertib (MLN8237) purchased from Selleck.

    Eg5 inhibition counteracts the induction of spindle pole fragmentation by Aurora-A inactivation. The protocol to inhibit Aurora-A by MLN8237 in cells progressing towards mitosis is depicted (time intervals not represented to scale). Control cultures were treated with solvent (DMSO) in the same time window. When indicated, MON was added 1 hour before harvesting. Note the absence of active phosphorylated (pThr288) Aurora-A (in red in IF panels) in cells treated with MLN8237. Upper histograms represent the percentage of all spindle and MT abnormalities in control and MLN8237-treated cultures (200 counted PM/M per condition in 2 experiments); the grey fraction of the histograms represents mitoses with spindle extrapoles, while other defects (monopolar or disorganised spindles, few and short MTs) are in white. Lower histograms and IF panels show that concomitant Eg5 inhibition by MON prevents MLN8237-induced spindle pole fragmentation (note the failure of centrosome migration reflecting Eg5 inactivation in lower IF panels). 200 PM/M per condition were counted in 2 experiments. Error bars represent s.d. **: p < 0.001, χ2 test. Red asterisks indicate significant differences with respect to DMSO controls, and black asterisks significant differences between Aurora-Ai mitoses with active or inactive Eg5. Scale bar: 10 μm

    Mol Cancer 2011 10, 131. Alisertib (MLN8237) purchased from Selleck.

Purity & Quality Control

Choose Selective Aurora Kinase Inhibitors

Biological Activity

Description Alisertib (MLN8237) is a selective Aurora A inhibitor with IC50 of 1.2 nM in a cell-free assay. It has >200-fold higher selectivity for Aurora A than Aurora B. Phase 3.
Features First orally available inhibitor of Aurora A.
Targets
Aurora A [1]
(Cell-free assay)
1.2 nM
In vitro

MLN8237 shows >200-fold higher selectivity for Aurora A than the structurally related Aurora B with an IC50 of 396.5 nM, and does not have any significant activity against 205 other kinases. [1] MLN8237 (0.5 μM) treatment inhibits the phosphorylation of Aurora A in MM1.S and OPM1 cells, without affecting the Aurora B mediated histone H3 phosphorylation. MLN8237 significantly inhibits cell proliferation in multiple myeloma (MM) cell lines with IC50 values of 0.003-1.71 μM. MLN8237 displays more potent anti-proliferation activity against primary MM cells and MM cell lines in the presence of BM stroma cells, as well as IL-6 and IGF-1 than against MM cells alone. MLN8237 (0.5 μM) induces 2- to 6-fold increase in G2/M phase in primary MM cells and cell lines, as well as significant apoptosis and senescence, involving the up-regulation of p53, p21 and p27, as well as PARP, caspase 3, and caspase 9 cleavage. In addition, MLN8237 shows strong synergistic anti-MM effect with dexamethasone, as well as additive effect with doxorubicin and bortezomib. [2] MLN8237 (0.5 μM) treatment causes the inhibition of colony formation of FLO-1, OE19, and OE33 esophageal adenocarinoma cell lines, and induces a significant increase in the percentage of polyploid cells, and subsequently an increase in the percentage of cells in the sub-G1 phase, which can be further enhanced in combination with cisplatin (2.5 μM), involving the higher induction of TAp73β, PUMA, NOXA, cleaved caspase-3, and cleaved PARP as compared with a single-agent treatment. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HCT116 M4rlW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHvvbHoxNjVizszN MoLTO|IhcA>? MlfQSG1UVw>? MWDJR|UxRTBwMESg{txO NVHyS|BlOjZzM{[2PFQ>
LS174T NWSwWVZRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MViwMlUh|ryP NEC1WnM4OiCq NF\CeIRFVVOR MWTJR|UxRTBwMEWg{txO MYKyOlE{PjZ6NB?=
T84 MmC5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXiwMlUh|ryP NGj3T|k4OiCq NFvmWYJFVVOR MVvJR|UxRTBwMEmg{txO NEXZXmIzPjF|Nk[4OC=>
LS180 Mm\0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIfI[JIxNjVizszN NF;Ye404OiCq M3LQNGROW09? Ml\hTWM2OD1zIN88US=> NHTvOm0zPjF|Nk[4OC=>
SW948 NE\IT3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1TLNlAvPSEQvF2= MkjmO|IhcA>? MlnWSG1UVw>? MV7JR|UxRTFizszN M1G2TFI3OTN4Nki0
HCT15 NFnTcVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlrRNE42KM7:TR?= MXy3NkBp NUTsTnhJTE2VTx?= MVXJR|UxRDBwNDFOwG0> NFy5cYUzPjF|Nk[4OC=>
DLD-1 MoP2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2fMT|AvPSEQvF2= M4f6XlczKGh? MlfoSG1UVw>? M2WyW2lEPTB:MD64JO69VQ>? NYnRdZJlOjZzM{[2PFQ>
MIP-101 M{nYU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnTvNE42KM7:TR?= MVS3NkBp MmHvSG1UVw>? M2L0VWlEPTB;MTFOwG0> NHflN3gzPjF|Nk[4OC=>
SNU1544 MkHOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVSyOXRMOC53IN88US=> MlnnO|IhcA>? MWDEUXNQ MVXJR|UxRTFizszN MoHQNlYyOzZ4OES=
OCI-Ly10 M2O0WGN6fG:2b4jpZ{BCe3OjeR?= M4LGVlczKGh? M{DqfmROW09? M1vycmlEPTB;MD6wOVgh|ryP MUiyOVg4QDN|MR?=
SU-DHL2 MoPHR5l1d3SxeHnjJGF{e2G7 NET5S2Y4OiCq M2DNbGROW09? MXfJR|UxRTBwMEGg{txO MYCyOVg4QDN|MR?=
OCI-LY7 NFLoe3BEgXSxdH;4bYMhSXO|YYm= MW[3NkBp M1rDZmROW09? MWHJR|UxRTBwMEixJO69VQ>? NF3kc2MzPTh5OEOzNS=>
SU-DHL6 NFTV[FVEgXSxdH;4bYMhSXO|YYm= MXS3NkBp MVfEUXNQ NYqyR2dTUUN3ME2wMlQ5OiEQvF2= M4na[FI2QDd6M{Ox
Jeko-1 NUHNVll6S3m2b4TvfIlkKEG|c3H5 NFLuWmQ4OiCq NITnepVFVVOR NYDofW1nUUN3ME2wMlAzQSEQvF2= Ml;1NlU5Pzh|M{G=
JVM-2 NX\KcpdES3m2b4TvfIlkKEG|c3H5 NVzSXlJGPzJiaB?= MXrEUXNQ MXjJR|UxRTBwMEGg{txO NY\oV444OjV6N{izN|E>
Rec-1 M4PB[2N6fG:2b4jpZ{BCe3OjeR?= MUO3NkBp NWfodGF7TE2VTx?= M3u3T2lEPTB;MD6wPFch|ryP M3;3VVI2QDd6M{Ox
Z-138 MXHDfZRwfG:6aXOgRZN{[Xl? Ml3uO|IhcA>? NF3CfZhFVVOR MnHoTWM2OD1yLkCxN{DPxE1? MYeyOVg4QDN|MR?=
H9 M1rDNmN6fG:2b4jpZ{BCe3OjeR?= NFPFV4w4OiCq MnPwSG1UVw>? MkT0TWM2OD1yLk[g{txO M4r0dVI2QDd6M{Ox
HH NFTpeZZEgXSxdH;4bYMhSXO|YYm= NYjmcZZiPzJiaB?= MWnEUXNQ MoDHTWM2OD1yLkeg{txO NYr5U28yOjV6N{izN|E>
DND41 M3Lx[GN6fG:2b4jpZ{BCe3OjeR?= M1i2VFczKGh? MnjwSG1UVw>? NYnDfmhFUUN3ME2wMlEh|ryP MWOyOVg4QDN|MR?=
CCL119 M1;GWWN6fG:2b4jpZ{BCe3OjeR?= MkfUO|IhcA>? NInlPZJFVVOR NHLvOpRKSzVyPUCuNFYzKM7:TR?= MoixNlU5Pzh|M{G=
J.Cam 1.6 NELBdmVEgXSxdH;4bYMhSXO|YYm= NXjvZoJZPzJiaB?= NYPFSGlNTE2VTx?= NE\HVI9KSzVyPUCuNVA2KM7:TR?= MXOyOVg4QDN|MR?=
Sup-T1 MWjDfZRwfG:6aXOgRZN{[Xl? NFS5bJE4OiCq M17hUGROW09? M3X0c2lEPTB;Mj6xOFIh|ryP MkTNNlU5Pzh|M{G=
Tib 152 NXLzOnB{S3m2b4TvfIlkKEG|c3H5 MUe3NkBp NHzke2VFVVOR MWHJR|UxRTBwODFOwG0> MXiyOVg4QDN|MR?=
MCF7 M4rDdGZ2dmO2aX;uJGF{e2G7 MVq1JO69VQ>? M1q1SlI1KGh? M4D5WWROW09? MW\JcoR2[2W|IFeyM20h[XK{ZYP0 M3LsOlI2QDN2NECx
MDA-MB-231 MULGeY5kfGmxbjDBd5NigQ>? MUW1JO69VQ>? MYmyOEBp MVTEUXNQ Mne1TY5lfWOnczDHN{9OKGG{cnXzeC=> MkXhNlU5OzR2MEG=
MCF7 M4DrWmZ2dmO2aX;uJGF{e2G7 NYno[5VNPSEQvF2= NFnYU4UzPCCq M1fy[2ROW09? MoLqSIVkemWjc3XzJJRp\SCneIDy[ZN{cW:wIHzleoVtKG:oIFPET|EwS0SFMh?= NFjpOXczPTh|NESwNS=>
MCF7 NXSzSGpwTnWwY4Tpc44hSXO|YYm= NIG1XGQ2KM7:TR?= MVOyOEBp MXzEUXNQ MnzkSIVkemWjc3XzJJRp\SCneIDy[ZN{cW:wIHzleoVtKG:oIFPET|I> Mn;jNlU5OzR2MEG=
MCF7 NWLPOplRTnWwY4Tpc44hSXO|YYm= M2XvXVUh|ryP M2rNfVI1KGh? M{\TfWROW09? MYnE[YNz\WG|ZYOgeIhmKGW6cILld5Nqd25ibHX2[Ywhd2ZiY4njcIlvKEJz MWiyOVg{PDRyMR?=
MCF7 NUfhSGxvTnWwY4Tpc44hSXO|YYm= M4X2fVUh|ryP NWOybZdlOjRiaB?= NVrLNmU4TE2VTx?= NH7mWHlKdmO{ZXHz[ZMhfGinIHX4dJJme3Orb36gcIV3\Wxib3[gdFIyKFejZkGvR4lxOQ>? NH3zeZozPTh|NESwNS=>
MCF7 NEe4[XhHfW6ldHnvckBCe3OjeR?= MVe1JO69VQ>? M3rCTVI1KGh? MmqwSG1UVw>? M{jVOmlv[3KnYYPld{B1cGViZYjwdoV{e2mxbjDs[ZZmdCCxZjDwNlchU2myMR?= MVOyOVg{PDRyMR?=
MDA-MB-231 NF\Id2NHfW6ldHnvckBCe3OjeR?= NV;VT|N1PSEQvF2= M2LkU|I1KGh? MmfOSG1UVw>? M3\1OGRm[3KnYYPld{B1cGViZYjwdoV{e2mxbjDs[ZZmdCCxZjDDSGsyN0OGQ{K= NIDjXJQzPTh|NESwNS=>
MDA-MB-231 NF3IWYdHfW6ldHnvckBCe3OjeR?= MYKxJO69VQ>? NFuxSXYzPCCq M2T3W2ROW09? MYrJcoNz\WG|ZYOgeIhmKGW6cILld5Nqd25ibHX2[Ywhd2ZiQ1TLNi=> NUnUe4FwOjV6M{S0NFE>
MDA-MB-231 Ml;wSpVv[3Srb36gRZN{[Xl? MkPXOUDPxE1? MnzHNlQhcA>? NXHNUlhLTE2VTx?= NXOyS5JRTGWlcnXhd4V{KHSqZTDlfJBz\XO|aX;uJIxmfmWuIH;mJIN6[2yrbjDCNS=> MUmyOVg{PDRyMR?=
MDA-MB-231 NHnkTYdHfW6ldHnvckBCe3OjeR?= NFPGZWI2KM7:TR?= NWG4TVB2OjRiaB?= MYjEUXNQ MWXJcoNz\WG|ZYOgeIhmKGW6cILld5Nqd25ibHX2[Ywhd2ZicEKxJHdi\jFxQ3nwNS=> NGPZN2szPTh|NESwNS=>
MDA-MB-231 NXPs[nRVTnWwY4Tpc44hSXO|YYm= NF\QdW02KM7:TR?= NF21UYkzPCCq NUXvRYFsTE2VTx?= NEWxTJhKdmO{ZXHz[ZMhfGinIHX4dJJme3Orb36gcIV3\Wxib3[gdFI4KEurcEG= NIrDNmQzPTh|NESwNS=>
MDA-MB-231 NFzaS4tHfW6ldHnvckBCe3OjeR?= NF[wO2s2KM7:TR?= NFW1dZAzPCCq MonFSG1UVw>? MmnmTY5kemWjc3XzJJRp\SCneIDy[ZN{cW:wIHzleoVtKG:oIIC1Ny=> NV[0eYg3OjV6M{S0NFE>
MCF7 Mn3mRZBweHSxc3nzJGF{e2G7 NV\WcJluPSEQvF2= MWiyOEBp MmnJSG1UVw>? MVfJcoR2[2W|IHHwc5B1d3SrYzDk[YF1cA>? MUOyOVg{PDRyMR?=
MDA-MB-231 MUnBdI9xfG:|aYOgRZN{[Xl? MWO1JO69VQ>? NYq4[mZTOjRiaB?= MXTEUXNQ NUXxOnhYUW6mdXPld{BieG:ydH;0bYMh\GWjdHi= M4PzVVI2QDN2NECx
MCF7 M4\TUmZ2dmO2aX;uJGF{e2G7 MkXxNUDPxE1? NW\FUYUyPzJiaB?= MkX5SG1UVw>? NEn3UFNKdmS3Y3XzJIF2fG:yaHHnbYMh\GWjdHi= NF\Rbo0zPTh|NESwNS=>
MDA-MB-231 NFXXeJBHfW6ldHnvckBCe3OjeR?= MYKxJO69VQ>? NX;GUI8yPzJiaB?= MlGxSG1UVw>? NGjwbIdKdmS3Y3XzJIF2fG:yaHHnbYMh\GWjdHi= NX\2[5JROjV6M{S0NFE>
U-2 OS NF:5cGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX21NEDPxE1? NIXabGkzPCCq NYPaXlZNTE2VTx?= MkPUTWM2OD1zNj62JO69VQ>? MlrkNlU4QTJ6MUG=
MG-63 NVn4fZo{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkjaOVAh|ryP NGPoTlgzPCCq M3\jUmROW09? MXrJR|UxRTlwNTFOwG0> M3r3WlI2Pzl{OEGx
U-2 OS M3v4[GFxd3C2b4Ppd{BCe3OjeR?= MkP1OUDPxE1? MoXoNlQhcA>? MlL3SG1UVw>? MlTxTY5lfWOnczDhdI9xfG:2aXOgZ4VtdCCmZXH0bC=> M1LOflI2Pzl{OEGx
MG-63 NYLRc|IxSXCxcITvd4l{KEG|c3H5 M3PTR|Uh|ryP MY[yOEBp M2nZXGROW09? NX\t[oRuUW6mdXPld{BieG:ydH;0bYMh[2WubDDk[YF1cA>? M4nITlI2Pzl{OEGx
U-2 OS NYjVenAyTnWwY4Tpc44hSXO|YYm= M3iye|Uh|ryP NXTDXYtHOjRiaB?= NIjDPGxFVVOR M3v5NHBzd22xdHXzJIF2fG:yaHHnbYMh[2WubDDk[YF1cA>? MXmyOVc6OjhzMR?=
MG-63 M4nEXmZ2dmO2aX;uJGF{e2G7 NH\INlU2KM7:TR?= MV2yOEBp NVLIU2ZWTE2VTx?= NH:5XGtRem:vb4Tld{BifXSxcHjh[4lkKGOnbHyg[IVifGh? MYSyOVc6OjhzMR?=
PANC-1 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUXWTG9jPTBizszN MX[yOEBp M4\yRWROW09? M3nZfmlEPTB;Nz6xJO69VQ>? NV2xR4p1OjV4M{KyNlU>
BxPC-3 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYnveHk5PTBizszN NI[wSIkzPCCq NGjpSWhFVVOR NELWWWZKSzVyPU[uPEDPxE1? MUKyOVY{OjJ{NR?=
PANC-1 NWqzNFRQTnWwY4Tpc44hSXO|YYm= NELRPGQ2KM7:TR?= MWWyOEBp M3TCTGROW09? NIPrWolKdmS3Y3XzJINmdGxiY4njcIUh[XK{ZYP0JIlvKEd{L12gdIhie2V? M3Ti[lI2PjN{MkK1
BxPC-3 MWjGeY5kfGmxbjDBd5NigQ>? M1XNNlUh|ryP NW\uV2F7OjRiaB?= MW\EUXNQ MUTJcoR2[2W|IHPlcIwh[3mlbHWgZZJz\XO2IHnuJGczN01icHjhd4U> NFrkW5YzPTZ|MkKyOS=>
PANC-1 MlG4SpVv[3Srb36gRZN{[Xl? MWO1JO69VQ>? NFTLVXUzPCCq MYXEUXNQ MnjlTY5lfWOnczDheZRweGijZ3njJINmdGxiZHXheIg> MofVNlU3OzJ{MkW=
BxPC-3 NIW3[|FHfW6ldHnvckBCe3OjeR?= NWTCW5lZPSEQvF2= NYi2WGlWOjRiaB?= MonVSG1UVw>? NETwW5JKdmS3Y3XzJIF2fG:yaHHnbYMh[2WubDDk[YF1cA>? NGC0UlYzPTZ|MkKyOS=>
SKOV3 NFLtO4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3O3eFExOCEQvF2= NIPze3YzPCCq NIHLPYhFVVOR NVK0dGFjUUN3ME2yNE41QCEQvF2= NUT2W4hHOjV4MkS3OVA>
OVCAR4 MnS3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MW[xNFAh|ryP NUL5WGNsOjRiaB?= MkTqSG1UVw>? M17tTGlEPTB;MkKuNVMh|ryP M1XVR|I2PjJ2N{Ww
SKOV3 NF7XSmFHfW6ldHnvckBCe3OjeR?= Mnn4OUDPxE1? NH;wOYs4OiCq MXfEUXNQ MkLBTY5lfWOnczDHNk9OKGG{cnXzeC=> NWTtVpFlOjV4MkS3OVA>
OVCAR4 MX\GeY5kfGmxbjDBd5NigQ>? MmXWOUDPxE1? NIfsbJg4OiCq NXXa[FJkTE2VTx?= MkGxTY5lfWOnczDHNk9OKGG{cnXzeC=> M2nTVVI2PjJ2N{Ww
SKOV3 NIXBXJNCeG:ydH;zbZMhSXO|YYm= NWLhZ4xbPSEQvF2= NGHvdmwzPCCq NEnucFdFVVOR M3PYfGlv\HWlZYOgZZBweHSxc3nz NVT5fFc3OjV4MkS3OVA>
OVCAR4 Mn7ERZBweHSxc3nzJGF{e2G7 NEmxfVk2KM7:TR?= M{e2S|I1KGh? NE\hPVFFVVOR M2XhZWlv\HWlZYOgZZBweHSxc3nz NX[3bmZZOjV4MkS3OVA>
AGS NYnUUYU4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlnaNlUh|ryP NILqdJYzPCCq MV7EUXNQ NYW4dY95UUN3ME2xPU4xQSEQvF2= MXWyOVYxQTl{Mx?=
NCI-N78 NX[ySHFbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWeyOUDPxE1? NHe2THUzPCCq M3vtSGROW09? M2m4XGlEPTB;Mk[uN|Mh|ryP M1HIc|I2PjB7OUKz
AGS NFOzUIFCeG:ydH;zbZMhSXO|YYm= MXy1JO69VQ>? MY[yOEBp NEL6blhFVVOR MY\JcoR2[2W|IHHwc5B1d3Orcx?= NH3FUXczPTZyOUmyNy=>
NCI-N78 MX3BdI9xfG:|aYOgRZN{[Xl? MlLxOUDPxE1? NHvXUWQzPCCq NILwSlZFVVOR NF\pWVFKdmS3Y3XzJIFxd3C2b4Ppdy=> NUS3V5pYOjV4MEm5NlM>
AGS MUTGeY5kfGmxbjDBd5NigQ>? MVq1JO69VQ>? MXmyOEBp MYnEUXNQ NHLoT21KdmS3Y3XzJJRp\SCjdYTvdIhi\3l? M4HUd|I2PjB7OUKz
NCI-N78 M{G5eGZ2dmO2aX;uJGF{e2G7 MWK1JO69VQ>? NYHUbI9HOjRiaB?= MoPySG1UVw>? NYDwe5ZLUW6mdXPld{B1cGViYYX0c5Bp[We7 M3O3elI2PjB7OUKz
HSC-3 NH7xb5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1vNSVEh|ryP M3j6e|Q5KGh? MnzJTWM2OD1yLkW0JO69VQ>? MWqyOVM3PjF2Mx?=
GB30 M3y0cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVmxJO69VQ>? M4SzT|ch\A>? M3zBZWROW09? Mm[5TWM2OD1yLkCxNUDPxE1? NVGwXoJiOjVzME[0Nlg>
GB9 NYLh[Vc6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlK5NUDPxE1? NELwfZM4KGR? MUHEUXNQ NHHQOnpKSzVyPUCuNFI1KM7:TR?= MUeyOVExPjR{OB?=
GB169 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEPjd4YyKM7:TR?= M{LQ[Fch\A>? NWDYOIttTE2VTx?= M{nEfWlEPTB;MD6wN|Ih|ryP MljyNlUyODZ2Mki=
T24 MV;GeY5kfGmxbjDBd5NigQ>? MXWxJO69VQ>? MnT2OFghcA>? MV\EUXNQ M4HzUGlv\HWlZYOgZ4VtdCCleXPs[UBienKnc4S= MUeyN|QxOzZ|Mx?=
RT4 MVTGeY5kfGmxbjDBd5NigQ>? NUfKTFN4OSEQvF2= NWTRWW1jPDhiaB?= NITzO2pFVVOR NVHXWoNwUW6mdXPld{Bk\WyuIHP5Z4xmKGG{cnXzeC=> MoO1NlM1ODN4M{O=
UM-UC-3 Mly0SpVv[3Srb36gRZN{[Xl? NWi0OGVTOSEQvF2= NWHQcIxNPDhiaB?= MX\EUXNQ M3nVTmlv\HWlZYOgZ4VtdCCleXPs[UBienKnc4S= MkPJNlM1ODN4M{O=
T24 MorKRZBweHSxc3nzJGF{e2G7 NYDMV5ZxOy5zNjFOwG0> NGPYR3I6PiCq MmroSG1UVw>? NYPxPVhxUUN3ME2wMlA{ODZizszN M2PhZ|I{PDB|NkOz
RT4 M2jTNmFxd3C2b4Ppd{BCe3OjeR?= M1Xn[FMvOTZizszN NIfuWJY6PiCq MlLLSG1UVw>? MkO4TWM2OD1yLkGxPVgh|ryP MYeyN|QxOzZ|Mx?=
UM-UC-3 MVnBdI9xfG:|aYOgRZN{[Xl? NFnx[lU{NjF4IN88US=> M3Pudlk3KGh? MYnEUXNQ MmfyTWM2OD1yLkC0OFkh|ryP MWeyN|QxOzZ|Mx?=
OVCAR-5 MWTGeY5kfGmxbjDBd5NigQ>? NWrNN3N[PTBibl2= NEnQboRKdmirYnn0d{Bk\WyuIH3p[5JifGmxbh?= MoLZNlM{OzR|Mke=
SKOV3ip2 Mnz2SpVv[3Srb36gRZN{[Xl? NVr6b4xGPTBibl2= M2P5SWlvcGmkaYTzJINmdGxibXnndoF1cW:w NVLJUYNKOjN|M{SzNlc>
S462 MnfZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYOxNFAh|ryP M1mwd|czKGh? MUfEUXNQ NV7ySXEzSXS2ZX71ZZRmeyClZXzsJIdzd3e2aB?= M2\WXVI{OzJ6MUG0
2884 NUTKW|ZsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1rqU|ExOCEQvF2= MYC3NkBp MUHEUXNQ NVjURnJ1SXS2ZX71ZZRmeyClZXzsJIdzd3e2aB?= M{m4dVI{OzJ6MUG0
2885 NGDJZ3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUSxNFAh|ryP NXvM[I0xPzJiaB?= MlzGSG1UVw>? MUjBeJRmdnWjdHXzJINmdGxiZ4Lve5Rp M3;0[|I{OzJ6MUG0
CRL-2396 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnjSNVAxKM7:TR?= NVLLdGJif2G2ZYK= NGL0b4FKSzVyPUCuNFkzKM7:TR?= MV:yN|E2OzV{NB?=
TIB-48 NWLSVlE3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXWxNFAh|ryP NV34elZ3f2G2ZYK= MmTMTWM2OD1yLkC4PEDPxE1? MmTNNlMyPTN3MkS=
CRL-2396 NEnEXllEgXSxdH;4bYMhSXO|YYm= M4rVSVEh|ryP M{n2dVQ5KGh? NWjtV4RIf2G2ZYK= NGLiVYhKdmS3Y3XzJIFxd3C2b4Ppdy=> M17hblI{OTV|NUK0
TIB-48 NUP6cXR3S3m2b4TvfIlkKEG|c3H5 NXnw[HVGOSEQvF2= NY\MOYRuPDhiaB?= NVLXR5Q1f2G2ZYK= MXrJcoR2[2W|IHHwc5B1d3Orcx?= M{TXclI{OTV|NUK0
AGS MU\DfZRwfG:6aXOgRZN{[Xl? MkL6NE42KM7:TR?= MWmyOEBp NI\vUnpFVVOR MUfE[YNz\WG|ZYOgZ4VtdCC|dYL2bZZidA>? M3m5UFIzQTd{NkGx
FLO-1 NXK4VZFDS3m2b4TvfIlkKEG|c3H5 MYiwMlUh|ryP Mn7CNlQhcA>? NVz5TmQ{TE2VTx?= NYTHdpByTGWlcnXhd4V{KGOnbHygd5Vzfmm4YXy= NEG0OJQzOjl5Mk[xNS=>
OE33 Mk\UR5l1d3SxeHnjJGF{e2G7 NX3ZdWI{OC53IN88US=> MVWyOEBp MV3EUXNQ MVzE[YNz\WG|ZYOgZ4VtdCC|dYL2bZZidA>? MYeyNlk4OjZzMR?=
SKLMS NV3BXIR1S3m2b4TvfIlkKEG|c3H5 NX3zZ2duPzVibl2= MU[5OkBp MoW0TY5lfWOnczDhdI9xfG:|aYO= NFH1UHIzOjh{MUm5Oy=>
Leio285 NXOzS2hyS3m2b4TvfIlkKEG|c3H5 NH3afWY4PSCwTR?= NGXFW2w6PiCq NXPVUopEUW6mdXPld{BieG:ydH;zbZM> NXmyTGl[OjJ6MkG5PVc>
Mes-Sa NWjsR2d1S3m2b4TvfIlkKEG|c3H5 Ml62O|Uhdk1? Mk\aPVYhcA>? NHSxNGVKdmS3Y3XzJIFxd3C2b4Ppdy=> NYGybHZNOjJ6MkG5PVc>
DAOY Mk\mR5l1d3SxeHnjJGF{e2G7 M1jOcFExKM7:TR?= M3PvflczKGh? NH3Q[FNFVVOR MXvJR|UxRTBwMESg{txO NVXUTnZ[OjJ4NkmzN|U>
IMR32 M1[yemN6fG:2b4jpZ{BCe3OjeR?= MWmxNEDPxE1? MUS3NkBp MVjEUXNQ M{D1O2lEPTB;MD6wN{DPxE1? MYOyNlY3QTN|NR?=
Molt-4 MlHaR5l1d3SxeHnjJGF{e2G7 NU\WT3poOTBizszN M2fvU|czKGh? NVLCTIJ[TE2VTx?= NFfEfZpKSzVyPUCuNFIh|ryP MU[yNlY3QTN|NR?=
MOLM-13 M2[xeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1jhe|Mh|ryP NIrBNXA4OiCq NXfidYJyTGmvaX7pd4hmeyClZXzsJJZq[WKrbHn0fS=> MXeyNlQ5QDJ2OR?=
HL-60 M4XMOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE\WRmY{KM7:TR?= MmXqO|IhcA>? M4fqT2RqdWmwaYPo[ZMh[2WubDD2bYFjcWyrdIm= NEjJ[HczOjR6OEK0PS=>
MV4-11 M1ex[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M37MOlMh|ryP MWG3NkBp MojQSIlucW6rc3jld{Bk\WyuII\pZYJqdGm2eR?= NXnqUmg4OjJ2OEiyOFk>
SKM-1 M1vsVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEPkUXY{KM7:TR?= NVTjSYdEPzJiaB?= NYXlcHl{TGmvaX7pd4hmeyClZXzsJJZq[WKrbHn0fS=> NV;sVph7OjJ2OEiyOFk>
SH2 NInENGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFXPeVc{KM7:TR?= M1e5SlczKGh? MUjEbY1qdmm|aHXzJINmdGxidnnhZoltcXS7 NYTIVIduOjJ2OEiyOFk>
NOMO-1 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXezJO69VQ>? M2XSfVczKGh? M3nQW2RqdWmwaYPo[ZMh[2WubDD2bYFjcWyrdIm= NUXNS5QxOjJ2OEiyOFk>
OCL-AML2 NI\zeFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIr4NYw{KM7:TR?= MWW3NkBp NGLQRZlFcW2rbnnzbIV{KGOnbHygeoli[mmuaYT5 MlLINlI1QDh{NEm=
PL-21 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY[zbWw6OyEQvF2= NHrO[Xk4OiCq MmS1SIlucW6rc3jld{Bk\WyuII\pZYJqdGm2eR?= MlX0NlI1QDh{NEm=
KG-1 NHXaVIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYKzJO69VQ>? MXi3NkBp NVLUdpA5TGmvaX7pd4hmeyClZXzsJJZq[WKrbHn0fS=> NV:xTpc5OjJ2OEiyOFk>
A172 NETiU3lEgXSxdH;4bYMhSXO|YYm= M4KxSFExOCEQvF2= M4LO[VI1KGh? NUXnUJRMTE2VTx?= MorFTWM2OD1yLkGyNEDPxE1? M4HiZ|IzOjd2M{m5
U87 NEnmV25EgXSxdH;4bYMhSXO|YYm= M3LNUFExOCEQvF2= NGPxbYEzPCCq MW\EUXNQ NEf1Z5FKSzVyPUCuNVA2KM7:TR?= NVq1ZYMyOjJ{N{SzPVk>
U251 MnLDR5l1d3SxeHnjJGF{e2G7 MXGxNFAh|ryP MlrUNlQhcA>? NWTpdZZxTE2VTx?= NVmwZocyUUN3ME2wMlExOCEQvF2= NUP5VJkyOjJ{N{SzPVk>
T98 NHTSd5ZEgXSxdH;4bYMhSXO|YYm= MWmxNFAh|ryP M2LENFI1KGh? MWnEUXNQ M3zlVmlEPTB;MD6xNlUh|ryP M3HzS|IzOjd2M{m5
LN18 M{jwbWN6fG:2b4jpZ{BCe3OjeR?= M3nM[lExOCEQvF2= MmXUNlQhcA>? M4LZbWROW09? NVHZ[m9bUUN3ME2wMlIyOCEQvF2= MW[yNlI4PDN7OR?=
LN443 MknZR5l1d3SxeHnjJGF{e2G7 MVOxNFAh|ryP NX:0SpVyOjRiaB?= MnvISG1UVw>? NGHJNJBKSzVyPUCuNlIxKM7:TR?= NEnQZ|UzOjJ5NEO5PS=>
HF66 MVzDfZRwfG:6aXOgRZN{[Xl? MnHQNVAxKM7:TR?= NUSyfGR[OjRiaB?= MmnVSG1UVw>? MmjjTWM2OD1yLkKyOUDPxE1? M1HYcFIzOjd2M{m5
HF2303 M{PjbGN6fG:2b4jpZ{BCe3OjeR?= MoLLNVAxKM7:TR?= NYfyNVVLOjRiaB?= MXTEUXNQ MoLvTWM2OD1yLkC2NEDPxE1? MnHaNlIzPzR|OUm=
HF2359 NHLaSXpEgXSxdH;4bYMhSXO|YYm= MnX1NVAxKM7:TR?= NInwOVIzPCCq MVvEUXNQ M1jTU2lEPTB;MD6wOlAh|ryP MoriNlIzPzR|OUm=
HF2414 NHrkd4ZEgXSxdH;4bYMhSXO|YYm= MWOxNFAh|ryP NWW3ZmFtOjRiaB?= NGK3R3dFVVOR NEi3VIFKSzVyPUCuNFgxKM7:TR?= MVSyNlI4PDN7OR?=
A-673 NF3s[I1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmjnNVAh|ryP M{TMR|k3KGh? MVPEUXNQ MX;JR|UxRTBwMEOyJO69VQ>? NWPKd4F3OjF2NEi1PVE>
TC-32 M2f4S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnnwNVAh|ryP MUK5OkBp NEnLU2hFVVOR M1fYOmlEPTB;MD6wN|kh|ryP NWrvNHhZOjF2NEi1PVE>
TC-71 NFfFVFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3T0PFExKM7:TR?= NY\ZVGlLQTZiaB?= MkX1SG1UVw>? MoHnTWM2OD1yLkGwNkDPxE1? M{\veVIyPDR6NUmx
SK-N-MC NEHkTmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIXQSpMyOCEQvF2= NEjWPXE6PiCq NVXLeJVPTE2VTx?= MlXZTWM2OD1yLkC3NkDPxE1? M3G4O|IyPDR6NUmx
CHLA-9 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH3KVpIyOCEQvF2= NYG3R2hGQTZiaB?= MV3EUXNQ MUHJR|UxRTBwMEG4JO69VQ>? MWWyNVQ1QDV7MR?=
CHLA-10 NEX2SnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlG0NVAh|ryP NIrHRYo6PiCq Ml3pSG1UVw>? MmHUTWM2OD1yLkC2NEDPxE1? NInMNYQzOTR2OEW5NS=>
CHLA-25 Ml;vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVixNEDPxE1? NHPLR4Y6PiCq NIXzd2tFVVOR M{DKV2lEPTB;MD6xOlgh|ryP MV[yNVQ1QDV7MR?=
CHLA-32 NFTJd4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHvjW|cyOCEQvF2= NX7iS|hjQTZiaB?= MVLEUXNQ MVvJR|UxRTBwMUO2JO69VQ>? M1rFbVIyPDR6NUmx
CHLA-56 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGfFOXkyOCEQvF2= MVe5OkBp MXvEUXNQ MnjkTWM2OD1zMDFOwG0> NUjXWG9IOjF2NEi1PVE>
CHLA-258 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnLPNVAh|ryP NF:4TJI6PiCq NGnrRYRFVVOR M{X0e2lEPTB;MD6xN|Ih|ryP MYWyNVQ1QDV7MR?=
COG-E-352 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX[xNEDPxE1? MkfGPVYhcA>? MnfjSG1UVw>? NGX3eJFKSzVyPUCuNFQ{KM7:TR?= MV2yNVQ1QDV7MR?=
CHLA-90 NVTXXGxuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4XPWVExKM7:TR?= NWHDTGNSQTZiaB?= NY[2TWd6TE2VTx?= M{O0NGlEPTB;MD6wOlEh|ryP MofkNlE1PDh3OUG=
CHLA-119 MnLMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXq3XlBXOTBizszN MlvSPVYhcA>? MYTEUXNQ Ml[0TWM2OD1yLkCyNkDPxE1? MUKyNVQ1QDV7MR?=
CHLA-122 M1XEe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFfGWXAyOCEQvF2= MmW3PVYhcA>? M1\MRmROW09? MVfJR|UxRTBwMEG5JO69VQ>? MVKyNVQ1QDV7MR?=
CHLA-136 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIHJbYMyOCEQvF2= MVO5OkBp NY\xbI13TE2VTx?= M3fzR2lEPTB;MD6wN|kh|ryP Mn\WNlE1PDh3OUG=
CHLA-140 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWmxNEDPxE1? MV:5OkBp NUXmNFF{TE2VTx?= Ml7ETWM2OD1yLkCyOkDPxE1? M2jEOFIyPDR6NUmx
LA-N-6 MoLMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYf5d2xROTBizszN NVjnfGloQTZiaB?= NXrLO3BJTE2VTx?= M2ixPGlEPTB;MD6wOVQh|ryP MnuxNlE1PDh3OUG=
NB-1643 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWexNEDPxE1? NGrBe486PiCq MmG0SG1UVw>? MYHJR|UxRTBwMEO3JO69VQ>? MVyyNVQ1QDV7MR?=
NB-EBc1 NVjuWmFtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUGxNEDPxE1? NYThb2p6QTZiaB?= MWLEUXNQ M1\LT2lEPTB;MD6wOVAh|ryP M33SflIyPDR6NUmx
SK-N-BE-1 MoHwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWHKOI03OTBizszN NHz0cZg6PiCq M1\PS2ROW09? NIezVm5KSzVyPUCuNFI5KM7:TR?= M2LZV|IyPDR6NUmx
SK-N-BE-2 M1fnb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnTWNVAh|ryP MlPTPVYhcA>? NEjMPG9FVVOR MoHPTWM2OD1yLkCzOkDPxE1? M2O2bFIyPDR6NUmx
SMS-KAN M33vNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUnhVlNTOTBizszN M{jTclk3KGh? NUXvOXhZTE2VTx?= MX\JR|UxRTBwMEO0JO69VQ>? NF:3Z4MzOTR2OEW5NS=>
SMS-KANR NW\TVFZbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkS5NVAh|ryP MoLKPVYhcA>? NHLsU3dFVVOR NV:0enliUUN3ME2wMlAzPiEQvF2= M2faclIyPDR6NUmx
SMS-KCN MmLZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXWxNEDPxE1? MnHOPVYhcA>? MX;EUXNQ MV3JR|UxRTBwMEG5JO69VQ>? MkC2NlE1PDh3OUG=
SMS-KCNR M13Nc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXS2PXVWOTBizszN MVm5OkBp MXTEUXNQ M4jhTGlEPTB;MD6wNVAh|ryP NV7Wc|BqOjF2NEi1PVE>
SMS-LHN NWG4[3RTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWCxNEDPxE1? MmLSPVYhcA>? MUDEUXNQ NFf4RnhKSzVyPUCuNFMzKM7:TR?= NHGzdWszOTR2OEW5NS=>
SMS-MSN MmT6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlXPNVAh|ryP NF[yd3k6PiCq NFvCRYZFVVOR NF7s[JlKSzVyPUCuNFIzKM7:TR?= MmDnNlE1PDh3OUG=
SMS-SAN MlfoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF\Cb3cyOCEQvF2= MojaPVYhcA>? M32xWmROW09? M1\i[WlEPTB;MD6wNlAh|ryP M1;jOFIyPDR6NUmx
Granta-4 MmnTR5l1d3SxeHnjJGF{e2G7 MkC2NVAh|ryP M1jBeVch\A>? M3nDdmlEPTB;MD6wOFAh|ryP NY\rd4hpOjF{OUG4Olc>
DB M3XlS2N6fG:2b4jpZ{BCe3OjeR?= M3G4NVExKM7:TR?= NUP5dXBnPyCm MojiTWM2OD1yLkC0NkDPxE1? MWOyNVI6OTh4Nx?=
RL MWXDfZRwfG:6aXOgRZN{[Xl? NWnYUIM6OTBizszN NEDOXI84KGR? M3P6eWlEPTB;MD6wNVUh|ryP MY[yNVI6OTh4Nx?=
K562 NVzCPJNmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUGxNEDPxE1? Ml\2PVYhcA>? M{LJZWlEPTB;MD6wPFch|ryP NV\peXRmOjFyOUG2N|M>
LAMA-84 M4DIZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUj3eJNUOTBizszN MVe5OkBp Mmi1TWM2OD1yLkC1O{DPxE1? MWGyNVA6OTZ|Mx?=
MM15 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4nPRVQh|ryP MkjzO|IhcA>? M{Pqd2ROW09? M2LEXWlEPTB;MD6xN{DPxE1? NIGycIczODN6Mki0OC=>
OPM1 M{\CNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE\ld2c1KM7:TR?= M{Oz[FczKGh? MY\EUXNQ NH\PTpdKSzVyPUCuNFMh|ryP MUGyNFM5Ojh2NB?=
RPM1 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIDn[JI1KM7:TR?= Mn61O|IhcA>? MnHESG1UVw>? NGHNZ4ZKSzVyPUGwMlMzKM7:TR?= MoTFNlA{QDJ6NES=
INA6 NEnZ[XZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mlz4OEDPxE1? M4n0cVczKGh? MlzqSG1UVw>? NUjrbpl[UUN3ME2wMlAxOiEQvF2= M{G4RVIxOzh{OES0
OPM2 MlvUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXfHR3RjPCEQvF2= M{XFXFczKGh? MXjEUXNQ MWPJR|UxRTRwM{eg{txO MYeyNFM5Ojh2NB?=
MM1R MmjWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3jkUVQh|ryP NYi5NZRTPzJiaB?= NF2wVotFVVOR NYXXb3lwUUN3ME2xMlY5KM7:TR?= NXL6PXlyOjB|OEK4OFQ>
DOX40 MmTQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlm5OEDPxE1? NGnRbmQ4OiCq NV\mNIMyTE2VTx?= M2qzfWlEPTB;NT60PEDPxE1? MYmyNFM5Ojh2NB?=
LR5 M2f1SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUC0JO69VQ>? M3fsTFczKGh? MorjSG1UVw>? NYrFOVI2UUN3ME2yMlU{KM7:TR?= NGfNT3QzODN6Mki0OC=>
U266 NWXBNIpkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVTNT|V1PCEQvF2= MWS3NkBp Mn3KSG1UVw>? NFy3UJhKSzVyPUGuOFMh|ryP MojxNlA{QDJ6NES=
RD MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2jZSFExKM7:TR?= M3;4bFk3KGh? MX\JR|UxRTBwMkK4JO69VQ>? MkezNlAyODh|M{i=
Rh41 NIDkUlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYDufFRpOTBizszN M{T1VVk3KGh? NYDsNHZyUUN3ME2wMlA6OCEQvF2= NUjlPZlYOjBzMEizN|g>
Rh30 NX\kNVk2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4nQS|ExKM7:TR?= M3\ZVVk3KGh? MkfsTWM2OD1yLkKzNEDPxE1? M3TJOFIxOTB6M{O4
BT-12 NGLWdFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn3YNVAh|ryP M4fFPFk3KGh? M1TQSWlEPTB;MD6wOlAh|ryP NUTtdlBJOjBzMEizN|g>
CHLA-266 MlHIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1G1[lExKM7:TR?= MXy5OkBp M2Tw[WlEPTB;MD6wO|Ih|ryP MWeyNFExQDN|OB?=
TC-71 M3XuTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mmq5NVAh|ryP NFLJcWc6PiCq NEO2N4hKSzVyPUCuNVAzKM7:TR?= M1[3ZVIxOTB6M{O4
SJ-GBM2 NF:3WGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkKwNVAh|ryP M{PKU|k3KGh? MX3JR|UxRTBwMEWwJO69VQ>? MUiyNFExQDN|OB?=
NALM-6 NYi4WVN[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;6W|B3OTBizszN NETWS3A6PiCq M1XvOmlEPTB;MD6wOlIh|ryP NHzDOIIzODFyOEOzPC=>
COG-LL-317 NHz2R3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXOxNEDPxE1? NVvjT3dVQTZiaB?= NFnG[FZKSzVyPUCuNFQ4KM7:TR?= M3fu[|IxOTB6M{O4
RS4-11 NFLUTnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWr5e|NIOTBizszN NIS2flc6PiCq M3jyUWlEPTB;MD6wNVgh|ryP NIfEXY0zODFyOEOzPC=>
MOLT-4 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEHOcYsyOCEQvF2= MmrWPVYhcA>? NGrnbYVKSzVyPUCuNFI3KM7:TR?= NWLRbWh6OjBzMEizN|g>
CCRF-CEM M2fq[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1nESVExKM7:TR?= M3LCZlk3KGh? MknDTWM2OD1yLkC5OEDPxE1? NV\xTYh1OjBzMEizN|g>
Kasumi-1 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4La[|ExKM7:TR?= NWf4bG57QTZiaB?= M3\JfmlEPTB;MD6xNFMh|ryP M4nhWlIxOTB6M{O4
Karpas-299 NWX5RZpIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\LeJIyOCEQvF2= MoS2PVYhcA>? MVfJR|UxRTBwMEO4JO69VQ>? M4KxN|IxOTB6M{O4
Ramos-RA1 NF\aSnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXKxNEDPxE1? Mk\qPVYhcA>? MlrHTWM2OD1yLkGyO{DPxE1? MlLPNlAyODh|M{i=

... Click to View More Cell Line Experimental Data

In vivo MLN8237 significantly reduces the tumor burden with tumor growth inhibition (TGI) of 42% and 80% at 15 mg/kg and 30 mg/kg, respectively, and prolongs the survival of mice compared with the control. [2]

Protocol

Kinase Assay:[1]
+ Expand

Aurora A radioactive Flashplate enzyme assay:

Aurora A radioactive Flashplate enzyme assay is conducted to determine the nature and degree of MLN8237-mediated inhibition in vitro. Recombinant Aurora A is expressed in Sf9 cells and purified with GST affinity chromatography. The peptide substrate for Aurora A is conjugated with biotin (Biotin-GLRRASLG). Aurora A kinase (5 nM) is assayed in 50 mM Hepes (pH 7.5), 10 mM MgCl2, 5 mM DTT, 0.05% Tween 20, 2 μM peptide substrate, 3.3 μCi/mL [γ-33P]ATP at 2 μM, and increasing concentrations of MLN8237 by using Image FlashPlates.
Cell Research:[2]
+ Expand
  • Cell lines: MM1.S, MM.1R, LR5, RPMI 8226, DOX40, OPM1, OPM2, INA6, and U266
  • Concentrations: Dissolved in DMSO, final concentrations ~10 μM
  • Incubation Time: 24, 48, and 72 hours
  • Method: Cells are exposed to various concentrations of MLN8237 for 24, 48, and 72 hours. Cells viability is measured using MTT assay, and cell proliferation is measured using 3[H]-thymidine incorporation. For cell cycle analysis, cells are permeabilized by 70% ethanol at -20 °C, and incubated with 50 μg/mL PI and 20 units/mL RNase-A. DNA content is analyzed by flow cytometry using BDFACS-Canto II and FlowJo software. For the detection of apoptosis and senescence, cells are stained with fluorescein isothiocyanate-annexin V and PI. Apoptotic cells are determined by flow cytometric analysis using BDFACS-Canto II and FlowJo software.
    (Only for Reference)
Animal Research:[2]
+ Expand
  • Animal Models: Severe combined immune-deficient (SCID) mice inoculated subcutaneously with MM1.S cells
  • Formulation: Formulated in 10% 2-hydroxypropyl-β-cyclodextrin/1% sodium bicarbonate
  • Dosages: ~30 mg/kg/day
  • Administration: Orally
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 27 mg/mL (52.03 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order:
15% Captisol
For best results, use promptly after mixing.
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 518.92
Formula

C27H20ClFN4O4

CAS No. 1028486-01-2
Storage powder
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02860000 Not yet recruiting Estrogen Receptor Negative|Estrogen Receptor Positive|HER2/Neu Negative|Postmenopausal|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Stage IV Breast Cancer Mayo Clinic|National Cancer Institute (NCI) December 2016 Phase 2
NCT02812056 Not yet recruiting Malignant Neoplasms of Digestive Organs|Malignant Neoplasms of Female Genital Organs|Malignant Neoplasms of Lip Oral Cavity and Pharynx|Malignant Neoplasms of Male Genital Organs M.D. Anderson Cancer Center|Millennium Pharmaceuticals, Inc. September 2016 Phase 1
NCT02700022 Recruiting Diffuse Large B-cell Lymphoma|Follicular Lymphoma|Burkitt Lymphoma UNC Lineberger Comprehensive Cancer Center|Millennium Pharmaceuticals, Inc. July 2016 Phase 1
NCT02719691 Recruiting Metastatic Breast Cancer|Solid Tumors University of Colorado, Denver May 2016 Phase 1
NCT02560025 Recruiting Acute Myeloid Leukemia Massachusetts General Hospital|Takeda December 2015 Phase 2
NCT02551055 Active, not recruiting Neoplasms, Advanced or Metastatic Millennium Pharmaceuticals, Inc.|Takeda October 2015 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    What is the suggested formulation of this compound for mouse injection(i.p.)?

  • Answer:

    It can be dissolved in 6% DMSO/50% PEG 300/5% Tween 80/ddH2O at 10 mg/ml as a clear solution.

Related Antibodies

Aurora Kinase Signaling Pathway Map

Aurora Kinase Inhibitors with Unique Features

Related Aurora Kinase Products

Tags: buy Alisertib (MLN8237) | Alisertib (MLN8237) supplier | purchase Alisertib (MLN8237) | Alisertib (MLN8237) cost | Alisertib (MLN8237) manufacturer | order Alisertib (MLN8237) | Alisertib (MLN8237) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID